2021 Fiscal Year Final Research Report
Characterization of drug transport in human adipose-derived stem cells and optimization in development of novel cell medicine with nephro-protective potency
| Project/Area Number |
19K07235
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 47060:Clinical pharmacy-related
|
|---|
| Research Institution | Osaka Medical and Pharmaceutical University (2021)
Osaka University of Pharmaceutical Sciences (2019-2020) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 脂肪幹細胞 / トランスポーター / 腎障害 |
|---|
| Outline of Final Research Achievements |
We characterized the mRNA expression level of various drug transporters in human adipose-derived stem cells (hAdSCs). Real-time PCR analyses revealed that the mRNA of OCTN1 and OCTN2 was clearly expressed in hAdSCs. Furthermore, mRNA of MRP1, MRP2, and MRP3 was detected, and the mRNA of OATP2B1 was expressed at much lower level.
The effect of hypoxia on expression and transporter activity of glucose transporter 1 (GLUT1) was investigated in hAdSCs because GLUT1 is one of well-known target gene of hypoxia-inducible factor-1 (HIF-1). The mRNA and protein expression of GLUT1 in hAdSCs were increased under hypoxic conditions comparing normoxic conditions. In addition, GLUT inhibitor phloretin-sensitive glucose uptake in hAdSCs was significantly enhanced under hypoxic conditions.
|
| Free Research Field |
薬剤学
|
| Academic Significance and Societal Importance of the Research Achievements |
現在、腎不全からの回復は腎移植以外に方法が確立されていないのが現状であり、新しい治療方法の開発は、患者のQOL向上や増え続ける医療費の抑制に繋がる。脂肪幹細胞は、再生医療への応用が期待されている。一方、障害組織への集積性を利用した脂肪幹細胞をDDSのディバイスとしての応用は、腎保護作用を有しながらも臓器移行性や薬物自身の薬理作用によって単独投与できない薬物を脂肪幹細胞に封入させることによって効率的に腎臓へ送達させる可能性を有し、新規腎指向型DDSとしての応用が期待される。
|
